The Maine Triple-Negative Breast Cancer Study

 
Genomic medicine promises better outcomes for cancer patients by using the genomic profile of a patient’s tumor to identify treatment options tailored to an individual. The Jackson Laboratory (JAX) has built a comprehensive platform for genome sequencing and drug efficacy studies to advance the development of novel, targeted cancer therapies. The foundation of this platform is a mouse (the “NSG” mouse) that can serve as a host for transplanted human cells and tissues. JAX has engrafted tumors from approximately 20 different types of cancer into NSG mice to build a living tumor bank of over 200 patient derived xenografts (PDX). 
 

Panels of PDX mice are ideally suited for “virtual clinical trials” to test experimental and existing therapies on a large scale and with high throughput. A focus of this MCF proposal is to validate that Triple Negative Breast Cancer tumors in PDX mice respond to drug treatment in the same way that the tumors in the patients responded. Platform validation is an essential step in the evolution of tumor xenografts as a method for prospective, individualized selection of cancer treatment, a concept we refer to as a Cancer Avatar.
 
Unlike traditional MCF-sponsored research, the goals of this proposal are not centered on cancer biology per se. Rather, we seek to validate the clinical relevance of the PDX platform and create a unique forum to facilitate statewide, multi-institution networking, collaboration, and education in genomic medicine. The Maine Triple Negative Breast Cancer pilot study will establish the technical and collaborative infrastructure needed to realize the transformative potential of Cancer Avatars in the future and to keep Maine at the forefront of the rapidly changing landscape in cancer research and clinical care.
 
Personnel:
  • Carol Bult, Ph.DCarol Bult, Ph.D. is a Professor at The Jackson Laboratory, co-Program Lead for The Jackson Laboratory Cancer Center and Program Leader for the PDX/Avatar program at The Jackson Laboratory. She will serve as the Primary Investigator and will be responsible for the overall organization and coordination for the project. Dr. Bult will also play a central role in the analysis of the tumor genome data and serve as a member of the Avatar Board and will present findings from tumor genome characterization.
  • Brandy Wilkinson, Ph.D. has served as the Study Director for JAX In Vivo Services since 2009. She will serve as the Study Director for the Triple Negative Breast Cancer Study and will be responsible for the expansion of existing PDX models, creation of new models, and the execution of the drug efficacy studies. Dr. Wilkinson will serve as a member of the Avatar Board and present the findings from drug efficacy studies.
     
  • Susan Airhart, B.S. is Senior Director for Strategic Alliances at The Jackson Laboratory. She, along with Neal Goodwin, Ph.D. established the JAX Human Tumor Consortium, which now includes 23 cancer centers from around the country. She is responsible for coordination of the collaborating institutions on the overall execution of this project. She will be a member of the Avatar Board.
     
  • Edison Liu, M.D. is President and CEO of The Jackson Laboratory. Dr. Liu is an international leader in cancer biology, genomics, human genetics and molecular epidemiology. Dr. Liu’s research background is in breast cancer and he has had a long career in breast cancer genomics. He will provide guidance in developing the Avatar Board concept and participate in the interpretation of the data generated from this study.
     
  • Margaret Chavaree, B.A. is Biorepository Coordinator for Eastern Maine Medical Center. As a Certified Tumor Registrar (CTR), She will promote study enrollment at EMMC; develop institutional protocols, and oversee tissue procurement and clinical data collection for EMMC. Ms. Chavaree has coordinated the collection and shipment of over 120 tumor samples from EMMC patients to date for the JAX PDX program. She will be an Avatar Board member.
     
  • Thomas Openshaw, M.D. is Head, Oncology Research, CancerCare of Maine, Eastern Maine Healthcare Systems. Dr. Openshaw will serve as an advisor for study design, drug selection and testing. He will serve as the co-clinical chair of the Avatar Board with Dr. Miesfeldt.
     
  • Ivette Emery, Ph.D. is Clinical and Translational Research Catalyst for Maine Medical Center Research Institute. She will promote study enrollment at MMC; develop the MMC institutional protocol, including creation of the IRB application and informed consent; and support data collection, participant recruitment and ongoing reporting to clinical teams. She also will oversee tissue procurement and clinical data collection for MMC. She will be an Avatar Board member.
     
  • Susan Miesfeldt, M.D. is Director, Maine Medical Center Cancer Risk and Prevention Program. Dr. Miesfeldt will serve as an advisor for study design, drug selection and testing. She also will promote study enrollment at MMC and develop the MMC institutional protocol, including creation of the IRB application and informed consent. She will serve as the co-clinical chair of the Avatar Board with Dr. Openshaw.

http://www.jax.org/news/archives/2013/virtual-clinical-trials.html

Organization: 
The Jackson Laboratory
Researcher: 
Carol J. Bult, Ph.D
Grant Amount Given: 
$212,601
Year Issued: 
2013
Period: 
Other
Grant Category: 
Research
Types of Cancer: 
Breast
Grant Duration: 
2 Year Accelerator Grant

Maine Cancer Foundation Grants to this Organization:

Year Program Amount Category Organization
2014 Genetic Testing for Primary Care Providers: Case-based Web Modules $49,220 Education The Jackson Laboratory
2014 A Secondary Syndrome: Acute Myeloid Leukemia $50,000 Research The Jackson Laboratory
2014 Are Micro RNAs the Key to Stopping Lung Cancer? $50,000 Research The Jackson Laboratory
2014 Mouse Models for Acute Myeloid Leukemia $169,834 Research The Jackson Laboratory
2014 A Slice of Life: The Search for Variation in Brain Tumors $50,000 Research The Jackson Laboratory
2013 Defining Susceptibility To Transformation By Epigenetic Landscape $49,999 Research The Jackson Laboratory
2013 The Maine Triple-Negative Breast Cancer Study $212,601 Research The Jackson Laboratory
2013 Assessing Therapeutic Potential of a New Drug ICG-001 in Glioblastoma $50,000 Research The Jackson Laboratory
2013 Development of Optimized Ex Vivo Organotypic Slice Culture Systems $164,686 Research The Jackson Laboratory
2012 FoxC2 Function in glioma stem cells and Vasculature $84,000 Research The Jackson Laboratory
2012 New Models for Lung Cancer Research $199,036 Research The Jackson Laboratory
2012 Online CME Course $27,600 Education The Jackson Laboratory
2011 Imaging Glicoma Stem Cell Dynamics in Vivo $90,000 Research The Jackson Laboratory
2010 MicroRNA Expression during Lung Tumor Progression $90,000 Research The Jackson Laboratory
2010 Genetic Chemotherapy: Inducing Leukemia and Lymphoma Cell Self Destruction $67,500 Research The Jackson Laboratory
2010 Notch Signaling in Medulloblastoma Initiation and Cancer Stem Cell Maintenance $90,000 Research The Jackson Laboratory
2009 Validating S100A6 as a Novel Marker and Potential Therapeutic Target of Brain Cancer Stem Cells $80,000 Research The Jackson Laboratory
2008 Development Genomics of Lung Cancer $79,524 Research The Jackson Laboratory
2008 Homologous Recombination Factor XRCC2 in B-Cell Genome Stability and Tumor Supression $79,696 Research The Jackson Laboratory
2006 Chromatin Reorganization in Pro-B Cell Lymphoma Nuclei $74,180 Research The Jackson Laboratory
2006 The Role of Src Kinases in Regulation of Stem Cell Survival in CML $75,000 Research The Jackson Laboratory
2005 A Gene Expression Study for the Hormone Independent Growth Transition of Ovarian Cancer Cells in vivo $20,000 Research The Jackson Laboratory
2004 Malignant Ovarian Granulose Cell Teumorigenesis $37,165 Research The Jackson Laboratory
2003 Parent-of-Origin Genetics in a Model of Ovarian Ganulosa Cell Tumorigenesis $35,500 Research The Jackson Laboratory